Graybug Vision, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Graybug Vision, Inc. - overview
Established
2011
Location
Redwood City, CA, US
Primary Industry
Pharmaceuticals
About
Founded in 2011 and based in California, US, Graybug Vision, Inc. is a clinical-stage pharmaceutical company that develops therapeutics for the treatment of ocular diseases such as glaucoma and corneal graft rejection. The company offers GB-102, a clinical-stage depot formulation for the treatment of wet age0-related degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).
Current Investors
OrbiMed Advisors, Hatteras Venture Partners, Clarus Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Optometrists & Opticians Products and Services, Pharmaceutical Research & Development
Website
www.graybug.vision
Company Stage
Series C/Round 3
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.